Journal article
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study
Abstract
BACKGROUND: Individuals with Li-Fraumeni syndrome have a high lifetime risk of developing cancer. We assessed the feasibility and potential clinical effect of a comprehensive surveillance protocol in asymptomatic TP53 mutation carriers in families with this syndrome.
METHODS: We implemented a clinical surveillance protocol, using frequent biochemical and imaging studies, for asymptomatic TP53 mutation carriers on Jan 1, 2004, and did a …
Authors
Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
Journal
The Lancet Oncology, Vol. 12, No. 6, pp. 559–567
Publisher
Elsevier
Publication Date
6 2011
DOI
10.1016/s1470-2045(11)70119-x
ISSN
1470-2045